Cyclacel Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Bio Green Med Solution, Inc. has entered into a definitive agreement to acquire Future NRG Sdn. Bhd. in an all-stock transaction to create a diversified environmental and safety services platform.
Bio Green Med Solution's CFO and Director, Kiu Cu Seng, acquired 200,000 shares of common stock at $1.40 per share.
Bio Green Med Solution's CEO, Doris Wong Sing Ee, acquired 300,178 shares of common stock at $1.4 per share, increasing her direct beneficial ownership to 1,111,131 shares.
Bio Green Med Solution Director Yap Kim Choy exchanged various Series Warrants for 467,535 shares of common stock and disposed of 28,540 shares on November 5, 2025.
Bio Green Med Solution's 10% owner and director, Ong Yee Lung, converted 467,535 warrants into an equal number of common stock shares.
A Bio Green Med Solution director and 10% owner exchanged various series of common stock warrants for 467,535 shares of common stock.
Bio Green Med Solution, Inc. Director and 10% owner Yap Kim Choy sold 112,260 shares of common stock.
Kua Khai Loon, a Director and 10% owner of Bio Green Med Solution, Inc., sold all 242,477 shares of common stock for $1.80 per share, eliminating beneficial ownership.
Bio Green Med Solution Director and 10% Owner Ong Yee Lung sold 248,814 shares of common stock, reducing direct beneficial ownership to zero.
Yap Kim Choy, a director and 10% owner of Bio Green Med Solution, Inc. (BGMS), sold 110,749 shares of common stock for $1.834 per share.
Yap Kim Choy, a Director and 10% owner of Bio Green Med Solution, Inc. (BGMS), reported the sale of 13,111 shares of common stock.
A director and 10% owner of Bio Green Med Solution, Inc. sold 120,250 shares of common stock at $2.118 per share.
Bio Green Med Solution's Director and 10% owner, Ong Yee Lung, sold 19,858 shares of common stock for $1.99 per share under a pre-arranged 10b5-1 plan.
Bio Green Med Solution, Inc. Director and 10% owner Yap Kim Choy sold 19,595 shares of common stock for $1.902 per share.
FITTERS Diversified Berhad, a 10% owner and director of Bio Green Med Solution, Inc., sold 92,352 shares of common stock for $3.005 per share.
FITTERS Diversified Berhad, a 10% owner and director of Bio Green Med Solution, Inc., reported the sale of 108,107 common shares.
Kua Khai Loon, a Director and 10% owner of Bio Green Med Solution, Inc., reported selling a significant number of common shares in two separate, pre-planned transactions.
FITTERS Diversified Berhad, a 10% owner and director of Bio Green Med Solution, Inc., reported the sale of 26,051 common shares at $5.50 per share.
A director and 10% owner of Bio Green Med Solution, Inc. has filed a Form 4 indicating a planned sale of common stock in October 2025.
A director and 10% owner of Bio Green Med Solution, Inc. sold 51,400 shares of common stock for $5.258 per share under a pre-arranged trading plan.
A director and 10% owner of Bio Green Med Solution, Inc. sold a total of 47,251 shares of common stock in two separate transactions.
FITTERS Diversified Berhad, a 10% owner and director of Bio Green Med Solution, Inc., reported the sale of 142,000 common shares at $5.293 per share.
Bio Green Med Solution, Inc. has completed its strategic acquisition of Fitters Sdn. Bhd., significantly diversifying its business into the fire protection and safety sector.
A director and 10% owner of Cyclacel Pharmaceuticals, Inc. has reported the sale of 19,054 shares of common stock.
Cyclacel Pharmaceuticals shareholders approved all three proposals at a special meeting, including a share issuance for Fitters Parent, a potential issuance of over 20% of common stock, and a corporate name change to Bio Green Med Solution, Inc.
A Cyclacel Pharmaceuticals director and 10% owner exchanged warrants for common stock but significantly reduced their overall common share holdings.
Kua Khai Loon, a Director and 10% owner of Cyclacel Pharmaceuticals, exchanged 186,465 Series C Warrants for an equal number of common shares.
Cyclacel Pharmaceuticals Director and 10% owner, Ong Yee Lung, exchanged Series C Common Stock Warrants for 186,465 shares of common stock.
Cyclacel Pharmaceuticals, Inc. filed a prospectus supplement detailing a $3 million private placement of Series F Preferred Stock and Warrants.
Cyclacel Pharmaceuticals announced its second quarter 2025 financial results, highlighted by a strategic share exchange agreement with FITTERS Diversified Berhad and a $3 million private placement.